National registry for renal angioplasty in patients with resistant hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study establishes a prospective national registry in Denmark for patients undergoing percutaneous transluminal renal angioplasty (PTRA) due to renal artery stenosis. It aims to collect data from high-risk patients selected based on national criteria and follows a standardized protocol across three participating centers. The registry will monitor patient outcomes and blood pressure control post-procedure, providing valuable insights into the effectiveness of PTRA in this population.

Why it matters

Who can join: the full rules

Eligibility criteria

1. True resistant hypertension (≥ 3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses) and uncontrolled blood pressure confirmed by 24-hour ambulatory blood pressure monitoring. The 24-hour ambulatory blood pressure monitoring is performed after nurse-administered medication and blood pressure measurements are performed hourly. If the average 24-hour ambulatory systolic blood pressure is ≥ 130 mmHg the patient can be evaluated for renal artery stenosis.
2. Hypertension and intolerance or side effects of the antihypertensive treatment. Hypertension is confirmed by 24-hour ambulatory blood pressure monitoring. The 24-hour ambulatory blood pressure monitoring is performed after nurse-administered medication and blood pressure measurements are performed hourly. If the average 24-hour ambulatory systolic blood pressure is ≥ 130 mmHg the patient can be evaluated for renal artery stenosis.
3. Progressive renal insufficiency (a reduction in eGFR \> 5 ml/min/1,73 m2 per year) in patients with bilateral renal artery stenosis or in patients with renal artery stenosis and only one kidney.
4. Recurrent heart failure/pulmonary edema and resistant hypertension (≥ 3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses) that may not be attributed to non-compliance, reduced left heart ventricular ejection fraction/heart valve disease or other obvious explanations (atrial fibrillation, fever, hyperthyroidism etc.). If the average 24-hour ambulatory systolic blood pressure is ≥ 130 mmHg after nurse-administered medication the patient can be evaluated for renal artery stenosis.
5. Younger patients (\< 40 years) with hypertension (24-hour ambulatory blood pressure monitoring ≥ 130/80 mmHg after nurse-administered medication )

Inclusion Criteria:

All of the following:

1. At least one of the above eligibility criteria
2. Duplex doppler ultrasonography or renography investigations consistent with hemodynamically significant renal artery stenosis
3. CT angiography or renal arteriography with angiographic renal artery stenosis of ≥ 70 % reduction of the luminal diameter in at least one projection

Exclusion Criteria:

1. If angiography/arteriography, ultrasonography or renography is consistent with bilateral significant renal artery stenosis and only one side is treated with PTRA
2. PTRA of a renal artery supplying a kidney which pre-PTRA handles ≤ 10% of the total kidney function (with no blockage of the renin-angiotensin system) and has a kidney size \< 7 cm (length)

Where it's running

• Aalborg University Hospital
  Aalborg, Denmark Recruiting
• Aarhus University Hospital
  Aarhus N, Denmark Recruiting
• Glostrup University Hospital/ Rigshospitalet
  Glostrup Municipality, Denmark Recruiting
• Holbaek Hospital
  Holbæk, Denmark Recruiting
• Odense University Hospital
  Odense C, Denmark Recruiting

Study contacts

• Study coordinator: Mark Reinhard, PhD
• Email: m.reinhard@dadlnet.dk
• Phone: +45 7845 2455

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NightWare use for cardiovascular health in women with PTSD-related nightmares

  This study tests whether NightWare can improve heart and kidney health biomarkers in premenopausal women who have PTSD-related nightmares.

  Recruiting at 2 sites University of Colorado, Denver · Aurora, Colorado and 1 other locations · NCT07021014

• Evaluating Enavogliflozin for Heart and Kidney Health in Type 2 Diabetes

  This study is testing if a new diabetes medication called enavogliflozin can improve heart and kidney health in adults with type 2 diabetes compared to other similar medications.

  Recruiting Phase 4 Yonsei University · Seoul · NCT06642623

• Using remote ischemic preconditioning to protect organs during hip surgery

  This study is testing if a special technique called remote ischemic preconditioning can help protect the hearts, kidneys, and brains of older patients during hip surgery.

  Recruiting University of Tartu · Tartu, Tartu · NCT06323018

• Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery

  This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07870941

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.